Taiwan · Delayed Price · Currency is TWD CH Biotech R&D Statistics
Total Valuation
CH Biotech R&D has a market cap or net worth of TWD 9.64 billion. The enterprise value is 10.09 billion.
| Market Cap | 9.64B |
| Enterprise Value | 10.09B |
Important Dates
The last earnings date was Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Aug 21, 2025 |
Share Statistics
CH Biotech R&D has 102.80 million shares outstanding. The number of shares has increased by 1.56% in one year.
| Current Share Class | 102.80M |
| Shares Outstanding | 102.80M |
| Shares Change (YoY) | +1.56% |
| Shares Change (QoQ) | -0.35% |
| Owned by Insiders (%) | 22.68% |
| Owned by Institutions (%) | 0.03% |
| Float | 37.05M |
Valuation Ratios
The trailing PE ratio is 22.08.
| PE Ratio | 22.08 |
| Forward PE | n/a |
| PS Ratio | 5.46 |
| PB Ratio | 3.68 |
| P/TBV Ratio | 3.69 |
| P/FCF Ratio | 58.86 |
| P/OCF Ratio | 30.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.68, with an EV/FCF ratio of 61.62.
| EV / Earnings | 22.98 |
| EV / Sales | 5.72 |
| EV / EBITDA | 12.68 |
| EV / EBIT | 17.13 |
| EV / FCF | 61.62 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.15 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.08 |
| Debt / FCF | 5.25 |
| Interest Coverage | 34.34 |
Financial Efficiency
Return on equity (ROE) is 16.76% and return on invested capital (ROIC) is 10.81%.
| Return on Equity (ROE) | 16.76% |
| Return on Assets (ROA) | 10.18% |
| Return on Invested Capital (ROIC) | 10.81% |
| Return on Capital Employed (ROCE) | 20.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.31 |
Taxes
In the past 12 months, CH Biotech R&D has paid 96.67 million in taxes.
| Income Tax | 96.67M |
| Effective Tax Rate | 18.04% |
Stock Price Statistics
The stock price has increased by +13.15% in the last 52 weeks. The beta is 0.17, so CH Biotech R&D's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +13.15% |
| 50-Day Moving Average | 102.15 |
| 200-Day Moving Average | 90.21 |
| Relative Strength Index (RSI) | 46.99 |
| Average Volume (20 Days) | 191,202 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CH Biotech R&D had revenue of TWD 1.77 billion and earned 439.33 million in profits. Earnings per share was 4.25.
| Revenue | 1.77B |
| Gross Profit | 1.49B |
| Operating Income | 590.81M |
| Pretax Income | 535.73M |
| Net Income | 439.33M |
| EBITDA | 770.46M |
| EBIT | 590.81M |
| Earnings Per Share (EPS) | 4.25 |
Balance Sheet
The company has 408.33 million in cash and 859.90 million in debt, giving a net cash position of -451.56 million or -4.39 per share.
| Cash & Cash Equivalents | 408.33M |
| Total Debt | 859.90M |
| Net Cash | -451.56M |
| Net Cash Per Share | -4.39 |
| Equity (Book Value) | 2.62B |
| Book Value Per Share | 25.51 |
| Working Capital | 129.07M |
Cash Flow
In the last 12 months, operating cash flow was 316.68 million and capital expenditures -152.86 million, giving a free cash flow of 163.81 million.
| Operating Cash Flow | 316.68M |
| Capital Expenditures | -152.86M |
| Free Cash Flow | 163.81M |
| FCF Per Share | 1.59 |
Margins
Gross margin is 84.29%, with operating and profit margins of 33.45% and 24.87%.
| Gross Margin | 84.29% |
| Operating Margin | 33.45% |
| Pretax Margin | 30.33% |
| Profit Margin | 24.87% |
| EBITDA Margin | 43.62% |
| EBIT Margin | 33.45% |
| FCF Margin | 9.27% |
Dividends & Yields
This stock pays an annual dividend of 4.10, which amounts to a dividend yield of 4.43%.
| Dividend Per Share | 4.10 |
| Dividend Yield | 4.43% |
| Dividend Growth (YoY) | 14.21% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 95.94% |
| Buyback Yield | -1.56% |
| Shareholder Yield | 2.84% |
| Earnings Yield | 4.56% |
| FCF Yield | 1.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2022. It was a forward split with a ratio of 1.15.
| Last Split Date | Jul 26, 2022 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
CH Biotech R&D has an Altman Z-Score of 6.35 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.35 |
| Piotroski F-Score | 6 |